Broader use of ARAKODA for persistent babesiosis
Treatments studied
Part of Infections clinical trials.
This trial tests ARAKODA (tafenoquine) for people with babesiosis that keeps coming back or doesn't get better with standard treatments. It aims to see if adding this medication helps clear the infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have a confirmed Babesia microti infection and are showing symptoms
- You have risk factors that make the infection more likely to return
- You've been treated with azithromycin, atovaquone, or clindamycin in the past 12 months and your doctor thinks the infection may still be there or has come back
- You are willing to start or continue a standard antibiotic treatment along with the study drug
- You can take oral medication and are not pregnant (or agree to use birth control if female)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding the oral drug tafenoquine to standard care works better than standard care plus a placebo for treating babesiosis, a tick-borne illness. You must be hospitalized with active symptoms.
This study tests an oral medication, tafenoquine, to see if it helps people with chronic babesiosis who have ongoing fatigue and other symptoms. It aims to find a better treatment for this tick-borne infection that keeps coming back.
This trial tests a combination of antimalarial drugs (tafenoquine plus artemisinin-based combination therapies) to see if it's safe and effective for treating vivax malaria. Participating may help clear the infection and prevent it from coming back.
This trial tests whether combining tafenoquine with other malaria medicines works better than a single drug for curing vivax malaria and preventing it from coming back. You would receive the study drugs and be monitored for about 6 months.
This trial tests a revised dose of a medicine called tafenoquine to more effectively cure vivax malaria (a type of malaria that can come back). It is for people with normal G6PD enzyme levels and a current fever from vivax malaria.
This study tests how a new malaria drug called tafenoquine moves through the body in healthy adults. It helps provide important safety and dosing information for future use.
Hear when a new Persistent Babesiosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.